Targeted OncologyLOXO-292 Induces 77% ORR in RET-Positive TumorsTargeted OncologyThe highly-selective RET inhibitor LOXO-292 induced an objective response rate (ORR) of 77% (95% CI, 58%-90%) for patients with RET fusion-positive non–small cell lung cancer (NSCLC), according to findings from the phase I LIBRETTO-001 study ...Loxo Oncology posts improved results for newest cancer drugReutersNew Data Helps Loxo's Cause in Developing Targeted Cancer DrugsBloombergLOXO-292 Shows Impressive Response Rates for RET-Positive TumorsOncLiveInvestor's Business Daily -STATall 10 news articles
Original Article: LOXO-292 Induces 77% ORR in RET-Positive Tumors – Targeted Oncology